Chris Ehrlich

Chris serves as a strategic advisor to the leadership team providing his valuable insights on biotechnology business development, corporate development, M&A and financial advisory. He is a highly accomplished business executive with over 25 years of experience across multiple industries. Chris currently serves as the CEO of Phoenix Biotech Acquisition Corp. and previously he was managing director and head of Locust Walk’s biopharma where he has led multiple transactions for emerging life sciences companies. Prior to Locust Walk, Chris was a managing director at InterWest Partners, a venture capital fund. There, he served on the boards of KAI Pharmaceuticals (acquired by Amgen) as the lead director, Biomimetic Therapeutics, Inc. (acquired by Wright Medical Technologies), Invuity (acquired by Stryker) and Xenon Pharmaceuticals. He graduated with an MBA from Kellogg School of Management in 1998 and has since held various executive roles in healthcare, technology, and financial services. Chris is widely recognized for his strategic leadership and his ability to drive growth and innovation.